BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
Number Citing Articles
1 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sohn W. Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma. Korean J Intern Med 2021;36:286-7. [PMID: 33725434 DOI: 10.3904/kjim.2021.078] [Reference Citation Analysis]
3 Huang JF, Hsieh MY, Wei YJ, Hung JY, Huang HT, Huang CI, Yeh ML, Huang CF, Jang TY, Hsu PY, Liang PC, Dai CY, Lin ZY, Yu ML, Chuang WL. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). Hepatol Int 2021. [PMID: 34850326 DOI: 10.1007/s12072-021-10275-7] [Reference Citation Analysis]
4 Solitano V, Aghemo A. Sofosbuvir in HCV patients with chronic kidney disease: No time for caution. Liver Int 2021;41:646-8. [PMID: 33730762 DOI: 10.1111/liv.14845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Garteiser P, Pagé G, d'Assignies G, Leitao HS, Vilgrain V, Sinkus R, Van Beers BE. Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography. Sci Rep 2021;11:19386. [PMID: 34588519 DOI: 10.1038/s41598-021-98726-x] [Reference Citation Analysis]
6 Hosseini-hooshyar S, Hajarizadeh B, Bajis S, Law M, Janjua NZ, Fierer DS, Chromy D, Rockstroh JK, Martin TCS, Ingiliz P, Hung C, Dore GJ, Martinello M, Matthews GV. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. The Lancet HIV 2022;9:e414-27. [DOI: 10.1016/s2352-3018(22)00077-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jiménez-Romero C, Justo I, Marcacuzco A, García V, Manrique A, García-Sesma Á, Calvo J, Caso Ó, Fernández I. Authors' response to Cai et al. on their commentary on "Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals" (Int J Surg 2021, 106096). Int J Surg 2021;95:106146. [PMID: 34688929 DOI: 10.1016/j.ijsu.2021.106146] [Reference Citation Analysis]
8 Tang Q, Wei L, Liu X, Hu P. Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience. Infect Drug Resist 2021;14:2297-307. [PMID: 34188496 DOI: 10.2147/IDR.S312902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Colombatto P, Palmisano E, Ricco G, Cavallone D, Oliveri F, Coco B, Salvati A, Romagnoli V, Surace L, Vatteroni M, Pistello M, Virdis A, Bonino F, Brunetto MR. Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy. JCM 2022;11:1406. [DOI: 10.3390/jcm11051406] [Reference Citation Analysis]
10 Isfordink CJ, van de Laar TJW, Rebers SPH, Wessels E, Molenkamp R, Knoester M, Baak BC, van Nieuwkoop C, van Hoek B, Brakenhoff SM, Blokzijl H, Arends JE, van der Valk M, Schinkel J. Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study. Open Forum Infect Dis 2021;8:ofab006. [PMID: 33614815 DOI: 10.1093/ofid/ofab006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Fernández de Cañete Camacho JC, Mancebo Martínez A, García Mena MA, Moreno Planas JM. Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. Gastroenterol Hepatol 2021:S0210-5705(21)00251-X. [PMID: 34543719 DOI: 10.1016/j.gastrohep.2021.09.003] [Reference Citation Analysis]
12 Lourenço MS, Zitelli PMY, Cunha-Silva M, Oliveira AIN, Oliveira CP, Sevá-Pereira T, Carrilho FJ, Pessoa MG, Mazo DF. Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil. World J Hepatol 2022; 14(1): 195-208 [DOI: 10.4254/wjh.v14.i1.195] [Reference Citation Analysis]
13 Jia Y, Yue W, Gao Q, Tao R, Zhang Y, Fu X, Liu Y, Liu L, Feng Y, Xia X. Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China. Microbiol Spectr 2021;9:e0029721. [PMID: 34479413 DOI: 10.1128/Spectrum.00297-21] [Reference Citation Analysis]
14 Compagnoni S, Bruno EM, Madonia G, Cannizzaro M, Madonia S. Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched. World J Gastroenterol 2021; 27(21): 2771-2783 [PMID: 34135553 DOI: 10.3748/wjg.v27.i21.2771] [Reference Citation Analysis]
15 Cabezas J, Llerena S, Mateo M, Álvarez R, Cobo C, González V, Martró E, Cuadrado A, Crespo J. Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences. Diagnostics (Basel) 2021;11:877. [PMID: 34068955 DOI: 10.3390/diagnostics11050877] [Reference Citation Analysis]
16 Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. Liver Int 2021;41:1802-14. [PMID: 33497016 DOI: 10.1111/liv.14797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Deng H, Guo F, Yu W, Li L, Xia Y, Guan Y, Li J. Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients. Virus Res 2021;302:198453. [PMID: 33991622 DOI: 10.1016/j.virusres.2021.198453] [Reference Citation Analysis]
18 McDonald SA, Barclay ST, Innes HA, Fraser A, Hayes PC, Bathgate A, Dillon JF, Went A, Goldberg DJ, Hutchinson SJ. Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality. J Viral Hepat 2021;28:1246-55. [PMID: 34002914 DOI: 10.1111/jvh.13543] [Reference Citation Analysis]
19 Rogers ME, Balistreri WF. Cascade of care for children and adolescents with chronic hepatitis C. World J Gastroenterol 2021; 27(12): 1117-1131 [PMID: 33828389 DOI: 10.3748/wjg.v27.i12.1117] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
20 Liu CH, Chen CY, Su WW, Tseng KC, Lo CC, Liu CJ, Chen JJ, Peng CY, Shih YL, Yang SS, Huang CS, Huang KJ, Chang CY, Tsai MC, Kao WY, Fang YJ, Chen PY, Su PY, Tseng CW, Huang JJ, Lee PL, Lai HC, Hsieh TY, Chang CH, Huang YJ, Lee FJ, Chang CC, Kao JH. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut 2022;71:176-84. [PMID: 33408122 DOI: 10.1136/gutjnl-2020-323569] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
21 Weigand K, Peschel G, Grimm J, Luu K, Schacherer D, Wiest R, Müller M, Schwarz H, Buechler C. Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiology. Eur J Immunol 2021. [PMID: 34914098 DOI: 10.1002/eji.202149488] [Reference Citation Analysis]
22 Romano C, Tortorella O, Dalla Mora L, Di Stasio D, Sellitto A, Adinolfi LE, Marrone A. Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. Front Immunol 2022;13:882064. [DOI: 10.3389/fimmu.2022.882064] [Reference Citation Analysis]
23 Barreto SG, Strasser SI, Mccaughan GW, Fink MA, Jones R, Mccall J, Munn S, Macdonald GA, Hodgkinson P, Jeffrey GP, Jaques B, Crawford M, Brooke-smith ME, Chen JW. Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0. Cancers 2022;14:2777. [DOI: 10.3390/cancers14112777] [Reference Citation Analysis]
24 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Pol S, Fouad F, Lemaitre M, Rodriguez I, Lada O, Rabiega P, Benabadji E, Roudot-Thoraval F. Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS). Lancet Reg Health Eur 2022;13:100281. [PMID: 34950924 DOI: 10.1016/j.lanepe.2021.100281] [Reference Citation Analysis]
26 Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 2021;13:1151. [PMID: 34208646 DOI: 10.3390/v13061151] [Reference Citation Analysis]
27 Dajti E, Marasco G, Ravaioli F, Alemanni LV, Rossini B, Colecchia L, Vestito A, Festi D, Colecchia A. The role of liver and spleen elastography in advanced chronic liver disease. Minerva Gastroenterol (Torino) 2021;67:151-63. [PMID: 34027932 DOI: 10.23736/S2724-5985.20.02793-2] [Reference Citation Analysis]
28 Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676 [PMID: 34904036 DOI: 10.4254/wjh.v13.i11.1663] [Reference Citation Analysis]
29 Tada T, Kurosaki M, Tamaki N, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Fujii H, Ishii T, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N. General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy. JGH Open. [DOI: 10.1002/jgh3.12778] [Reference Citation Analysis]
30 Mohammed AS, Balapure A, Khan AA, Khaja MN, Ganesan R, Dutta JR. Genotyping simplified: rationally designed antisense oligonucleotide-mediated PCR amplification-free colorimetric sensing of viral RNA in HCV genotypes 1 and 3. Analyst 2021;146:4767-74. [PMID: 34231566 DOI: 10.1039/d1an00590a] [Reference Citation Analysis]
31 Husa P, Snopkova S, Zavrelova J, Zlamal F, Svacinka R, Husa P. Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021;165:146-51. [PMID: 33928944 DOI: 10.5507/bp.2021.023] [Reference Citation Analysis]
32 Enomoto M, Vutien P, Kawada N. Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance? Hepatol Commun 2022;6:445-7. [PMID: 35202513 DOI: 10.1002/hep4.1864] [Reference Citation Analysis]
33 Kuntzen C, Bagha Z. The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.012] [Reference Citation Analysis]
34 Cheng PN, Mo LR, Chen CT, Chen CY, Huang CF, Kuo HT, Lo CC, Tseng KC, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Chou KH, Kao CN, Tsai PC, Liu CH, Lee MH, Cheng CY, Tsai MC, Liu CJ, Dai CY, Lin HC, Kao JH, Chuang WL, Yu ML; TACR investigators. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. Infect Dis Ther 2021. [PMID: 34967920 DOI: 10.1007/s40121-021-00576-7] [Reference Citation Analysis]
35 Chen CT, Lu MY, Hsieh MH, Tsai PC, Hsieh TY, Yeh ML, Huang CI, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Huang CF, Huang JF, Dai CY, Chuang WL, Shih YL, Yu ML. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. World J Gastroenterol 2022; 28(2): 263-274 [DOI: 10.3748/wjg.v28.i2.263] [Reference Citation Analysis]
36 Yeung A, Palmateer NE, Dillon JF, McDonald SA, Smith S, Barclay S, Hayes PC, Gunson RN, Templeton K, Goldberg DJ, Hickman M, Hutchinson SJ. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. J Hepatol 2021:S0168-8278(21)02103-6. [PMID: 34634387 DOI: 10.1016/j.jhep.2021.09.038] [Reference Citation Analysis]
37 Tada T, Nishimura T, Matono T, Yoshida M, Yuri M, Fujiwara A, Yuri Y, Takashima T, Aizawa N, Ikeda N, Enomoto H, Kumada T, Iijima H. Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Hepatol Res 2021;51:860-9. [PMID: 34046970 DOI: 10.1111/hepr.13677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Cornberg M, Ahumada A, Aghemo A, Andreoni M, Bhagat A, Butrymowicz I, Carmiel M, Chodick G, Conway B, Song Y, Gasbarrini A, Hüppe D, Plaza FJ, Lampertico P, Alonso MLM, Myles L, Persico M, Ramji A, Sarrazin C, Villa E, Weil C, Otano JIU; CREST Study Group. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study. Adv Ther 2022. [PMID: 35543964 DOI: 10.1007/s12325-022-02158-6] [Reference Citation Analysis]
39 Wong YJ, Nguyen MH. Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA? Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2021.12.037] [Reference Citation Analysis]
40 Ding YJ, Lu CK, Chen WM, Tung SY, Wei KL, Shen CH, Hsieh YY, Yen CW, Chang KC, Chiu WN, Hung CH, Lu SN, Chang TS. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis. J Gastroenterol Hepatol 2021. [PMID: 33978973 DOI: 10.1111/jgh.15546] [Reference Citation Analysis]
41 Hsieh M, Kao T, Hsieh T, Kao C, Peng C, Lai H, Chuang P, Kao J. Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study. Therapeutic Advances in Chronic Disease 2022;13:204062232110676. [DOI: 10.1177/20406223211067631] [Reference Citation Analysis]
42 Shumbusho F, Liu AF, Kateera F, Kabahizi J, Nsanzaimana S, Serumondo J, Damascene Makuza J, Grant PM, Musabeyezu E, Muvunyi C, Gupta N. Risk factors for difficult-to-treat hepatitis C virus genotype 4r in Rwanda and implications for elimination in sub-Saharan Africa. J Viral Hepat 2021;28:682-6. [PMID: 33421247 DOI: 10.1111/jvh.13467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Bartres C, Soy G, Forns X. Hepatitis C therapy and anticonvulsants. Gastroenterol Hepatol 2021;44:536. [PMID: 33253770 DOI: 10.1016/j.gastrohep.2020.11.003] [Reference Citation Analysis]
44 Carrasco T, Barquín D, Ndarabu A, Fernández-Alonso M, Rubio-Garrido M, Carlos S, Makonda B, Holguín Á, Reina G. HCV Diagnosis and Sequencing Using Dried Blood Spots from Patients in Kinshasa (DRC): A Tool to Achieve WHO 2030 Targets. Diagnostics (Basel) 2021;11:522. [PMID: 33804260 DOI: 10.3390/diagnostics11030522] [Reference Citation Analysis]
45 Marascio N, Costantino A, Taffon S, Lo Presti A, Equestre M, Bruni R, Pisani G, Barreca GS, Quirino A, Trecarichi EM, Costa C, Mazzitelli M, Serapide F, Matera G, Torti C, Liberto MC, Ciccaglione AR. Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy. J Clin Med 2021;10:1655. [PMID: 33924449 DOI: 10.3390/jcm10081655] [Reference Citation Analysis]
46 Varotti G, Dodi F, Paoletti E, Bruno A, Fontana I. Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient. Case Rep Transplant 2021;2021:1948560. [PMID: 34931152 DOI: 10.1155/2021/1948560] [Reference Citation Analysis]
47 Ridruejo E, Piñero F, Mendizabal M, Silva M; Latin American Liver Research Educational, Awareness Network (LALREAN). Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection. J Viral Hepat 2021;28:446-7. [PMID: 33147362 DOI: 10.1111/jvh.13433] [Reference Citation Analysis]
48 Hüppe D, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, Hidde D, Lohmann K, Bondin M, Wedemeyer H. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021. [PMID: 34339561 DOI: 10.1111/jvh.13586] [Reference Citation Analysis]
49 D'Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, Iavarone M, Tosetti G, Perbellini R, Sangiovanni A, Sypsa V, Lampertico P. Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2021:S0168-8278(21)02043-2. [PMID: 34592366 DOI: 10.1016/j.jhep.2021.09.013] [Reference Citation Analysis]
50 Tronina O, Durlik M, Orłowska I, Lorenc B, Łapiński TW, Garlicki A, Dybowska D, Zarębska-Michaluk D, Tudrujek-Zdunek M, Citko J, Janczewska E, Kaczmarczyk M, Jaroszewicz J, Krygier R, Klapaczyński J, Dobracka B, Białkowska-Warzecha J, Piekarska A, Simon K, Halota W, Pawłowska M, Tomasiewicz K, Flisiak R. Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. Ann Gastroenterol 2021;34:438-46. [PMID: 33948071 DOI: 10.20524/aog.2021.0595] [Reference Citation Analysis]
51 Mandorfer M, Turon F, Lens S, Baiges A, García-Criado Á, Darnell A, Belmonte E, Ferrusquía-Acosta J, Magaz M, Perez-Campuzano V, Olivas P, Bauer D, Casanovas G, Torres F, Mariño Z, Forns X, Hernández-Gea V, García-Pagán JC. Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. Liver Int 2021. [PMID: 34242479 DOI: 10.1111/liv.15009] [Reference Citation Analysis]
52 Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawłowska M, Halota W, Mazur W, Lorenc B, Janocha-Litwin J, Simon K, Piekarska A, Berak H, Klapaczyński J, Stępień P, Sobala-Szczygieł B, Citko J, Socha Ł, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Dobracka B, Krygier R, Białkowska-Warzecha J, Laurans Ł, Flisiak R. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. J Clin Med 2021;10:3280. [PMID: 34362064 DOI: 10.3390/jcm10153280] [Reference Citation Analysis]
53 Von den Hoff DW, Berden FAC, Schellekens AFA. If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. United European Gastroenterol J 2021;9:1101-2. [PMID: 34687156 DOI: 10.1002/ueg2.12167] [Reference Citation Analysis]
54 Klinker H, Naumann U, Rössle M, Berg T, Bondin M, Lohmann K, Koenig B, Zeuzem S, Cornberg M. Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. Liver Int 2021;41:1518-22. [PMID: 33966349 DOI: 10.1111/liv.14937] [Reference Citation Analysis]
55 Pabjan P, Brzdęk M, Chrapek M, Dziedzic K, Dobrowolska K, Paluch K, Garbat A, Błoniarczyk P, Reczko K, Stępień P, Zarębska-Michaluk D. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals? Viruses 2022;14:96. [PMID: 35062302 DOI: 10.3390/v14010096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Marcos-Fosch C, Cabezas J, Crespo J, Buti M. Anti-epileptic drugs and hepatitis C therapy: Real-world experience. J Hepatol 2021;75:984-5. [PMID: 34126106 DOI: 10.1016/j.jhep.2021.05.040] [Reference Citation Analysis]
57 D'Ambrosio R, Lampertico P. Is it time to refine HCC surveillance strategies in HCV cured patients? Hepatology 2022. [PMID: 35218241 DOI: 10.1002/hep.32430] [Reference Citation Analysis]
58 Tacke F, Klinker H, Boeker KHW, Merle U, Link R, Buggisch P, Hüppe D, Cornberg M, Sarrazin C, Wedemeyer H, Berg T, Mauss S; DHC-R. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry. Hepatol Commun 2022. [PMID: 35666055 DOI: 10.1002/hep4.2015] [Reference Citation Analysis]
59 Mangia A, Cotugno R, Cocomazzi G, Squillante MM, Piazzolla V. Hepatitis C virus micro-elimination: Where do we stand? World J Gastroenterol 2021; 27(16): 1728-1737 [PMID: 33967553 DOI: 10.3748/wjg.v27.i16.1728] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Alkhatib M, Di Maio VC, De Murtas V, Polilli E, Milana M, Teti E, Fiorentino G, Calvaruso V, Barbaliscia S, Bertoli A, Scutari R, Carioti L, Cento V, Santoro MM, Orro A, Maida I, Lenci I, Sarmati L, Craxì A, Pasquazzi C, Parruti G, Babudieri S, Milanesi L, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F, Svicher V, Salpini R, On Behalf Of Hirma Hepatocarcinoma Innovative Research MArkers And Fondazione Vironet C Hcv Virology Italian Resistance. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. Viruses 2021;13:743. [PMID: 33922732 DOI: 10.3390/v13050743] [Reference Citation Analysis]
61 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
62 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Brown RS Jr, Collins MA, Strasser SI, Emmett A, Topp AS, Burroughs M, Ferreira R, Feld JJ. Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infect Dis Ther 2022. [PMID: 35174470 DOI: 10.1007/s40121-022-00599-8] [Reference Citation Analysis]
64 Peschel G, Grimm J, Gülow K, Müller M, Buechler C, Weigand K. Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury. Diagnostics (Basel) 2020;10:E974. [PMID: 33228201 DOI: 10.3390/diagnostics10110974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
65 Turnes J, Rincón D, Calleja JL, Delgado MB, Rosales JM, Andrade RJ, Manzano ML, Salmerón FJ, López MA, Calvo M, Gómez J, Molina E, Frias YN, Gálvez-Fernández RM, Vallejo-Senra N, París S, Santos de Lamadrid R, Olveira A. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study. Gastroenterol Hepatol 2021:S0210-5705(21)00198-9. [PMID: 34129903 DOI: 10.1016/j.gastrohep.2021.05.015] [Reference Citation Analysis]
66 Chevaliez S, Roudot-Thoraval F, Hézode C, Pawlotsky JM, Njouom R. Performance of rapid diagnostic tests for HCV infection in serum or plasma. Future Microbiol 2021;16:713-9. [PMID: 34227402 DOI: 10.2217/fmb-2020-0295] [Reference Citation Analysis]
67 Galal G, Tammam H, Abdel Aal A, Fahmy N, Sheneef A, Ahmed N, Zaghloul A. Role of Lymphotoxin-α Gene Polymorphism in Hepatitis C Virus-Related Chronic Liver Disorders. Infect Drug Resist 2021;14:1921-30. [PMID: 34079302 DOI: 10.2147/IDR.S306879] [Reference Citation Analysis]
68 Nageswara Rao D, Zephyr J, Henes M, Chan ET, Matthew AN, Hedger AK, Conway HL, Saeed M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. J Med Chem 2021;64:11972-89. [PMID: 34405680 DOI: 10.1021/acs.jmedchem.1c00554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Chen YC, Li CH, Ko PH, Lee CC, Syu RJ, Tseng CW, Tseng KC. Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals. PLoS One 2021;16:e0256505. [PMID: 34437608 DOI: 10.1371/journal.pone.0256505] [Reference Citation Analysis]
70 Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ; REACT study group., Protocol Steering Committee., Coordinating Centre., Site Principal Investigators. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol 2021:S0168-8278(21)00336-6. [PMID: 34023350 DOI: 10.1016/j.jhep.2021.04.056] [Reference Citation Analysis]
71 Jachs M, Binter T, Chromy D, Schalk H, Pichler K, Bauer D, Simbrunner B, Hartl L, Schmidbauer C, Mayer F, Strassl R, Mandorfer M, Gschwantler M, Reiberger T. Outcomes of an HCV elimination program targeting the Viennese MSM population. Wien Klin Wochenschr 2021;133:635-40. [PMID: 34181068 DOI: 10.1007/s00508-021-01898-9] [Reference Citation Analysis]
72 Chemello L, Cavalletto L, Ferrari S, Monaco S. Impact of direct acting antivirals (DAA) on neurologic disorders in chronic hepatitis C. Minerva Gastroenterol (Torino) 2021;67:234-43. [PMID: 34672486 DOI: 10.23736/S2724-5985.21.02865-5] [Reference Citation Analysis]
73 Flower B, McCabe L, Le Ngoc C, Le Manh H, Le Thanh P, Dang Trong T, Vo Thi T, Vu Thi Kim H, Nguyen Tat T, Phan Thi Hong D, Nguyen Thi Chau A, Dinh Thi T, Tran Thi Tuyet N, Tarning J, Kingsley C, Kestelyn E, Pett SL, Thwaites G, Nguyen Van VC, Smith D, Barnes E, Ansari MA, Turner H, Rahman M, Walker AS, Day J, Cooke GS. High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. Open Forum Infect Dis 2021;8:ofab267. [PMID: 34337093 DOI: 10.1093/ofid/ofab267] [Reference Citation Analysis]
74 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Reference Citation Analysis]
75 Garrigou O, Ortonne V, Soulier A, Chevaliez S. Dried blood spot sampling for hepatitis C virus infection: A new tool to simplify testing algorithms. J Clin Virol 2021;141:104876. [PMID: 34126544 DOI: 10.1016/j.jcv.2021.104876] [Reference Citation Analysis]
76 Dai CY, Huang JF, Chuang WL, Yu ML. DAA Therapy in Hepatitis C in Patients With Chronic Kidney Disease: New Information for GFR Category G4 and G5. Clin Gastroenterol Hepatol 2022;20:246-7. [PMID: 33248105 DOI: 10.1016/j.cgh.2020.10.023] [Reference Citation Analysis]
77 Tada T, Kumada T, Matono T, Nakamura S, Sue M, Matsuo Y, Takatani M, Iijima H, Tanaka J. Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct‐acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance. JGH Open. [DOI: 10.1002/jgh3.12774] [Reference Citation Analysis]
78 Saracco GM, Marzano A, Rizzetto M. Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel? Biomedicines 2022;10:534. [DOI: 10.3390/biomedicines10030534] [Reference Citation Analysis]
79 Marcellusi A, Mennini FS, Ruf M, Galli C, Aghemo A, Brunetto MR, Babudieri S, Craxi A, Andreoni M, Kondili LA. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. Liver Int 2021. [PMID: 34582627 DOI: 10.1111/liv.15070] [Reference Citation Analysis]
80 Kaps L, Ahlbrand CJ, Gadban R, Nagel M, Labenz C, Klimpke P, Holtz S, Boedecker S, Michel M, Kremer WM, Hilscher M, Galle PR, Kraus D, Schattenberg JM, Weinmann-Menke J. Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care. PLoS One 2021;16:e0249342. [PMID: 33793644 DOI: 10.1371/journal.pone.0249342] [Reference Citation Analysis]
81 Aranday-Cortes E, McClure CP, Davis C, Irving WL, Adeboyejo K, Tong L, da Silva Filipe A, Sreenu V, Agarwal K, Mutimer D, Stone B, Cramp ME, Thomson EC, Ball JK, McLauchlan J. Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa. J Infect Dis 2021:jiab110. [PMID: 33668068 DOI: 10.1093/infdis/jiab110] [Reference Citation Analysis]
82 Su PY, Chen YY, Lai JH, Chen HM, Yao CT, Liu IL, Zeng YH, Huang SP, Hsu YC, Wu SS, Siao FY, Yen HH. Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study. J Clin Med 2021;10:5236. [PMID: 34830518 DOI: 10.3390/jcm10225236] [Reference Citation Analysis]
83 Martin MT, Patel S, Kulik L, Chan C. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings. Journal of Hepatology 2021;75:251-4. [DOI: 10.1016/j.jhep.2021.02.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
84 Lo C, Huang C, Cheng P, Tseng K, Chen C, Kuo H, Huang Y, Tai C, Peng C, Bair M, Chen C, Yeh M, Lin C, Lin C, Lee P, Chong L, Hung C, Chang TS, Huang J, Yang C, Hu J, Lin C, Chen C, Wang C, Su W, Hsieh T, Lin C, Tsai W, Lee T, Chen G, Wang S, Chang C, Mo L, Yang S, Wu W, Huang C, Hsiung C, Kao C, Tsai P, Liu C, Lee M, Liu C, Dai C, Chuang W, Lin H, Kao J, Yu M. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.01.012] [Reference Citation Analysis]
85 Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson EC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. J Hepatol 2021;75:462-73. [PMID: 33974951 DOI: 10.1016/j.jhep.2021.04.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Dammacco F, Lauletta G, Vacca A. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clin Exp Med. [DOI: 10.1007/s10238-022-00808-1] [Reference Citation Analysis]
87 Solomon SS, Wagner-cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00397-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Tada T, Kurosaki M, Tamaki N, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N. A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. JGH Open 2022;6:20-8. [PMID: 35071784 DOI: 10.1002/jgh3.12690] [Reference Citation Analysis]
89 Bradshaw D, Bibby DF, Manso CF, Piorkowska R, Mohamed H, Ledesma J, Bubba L, Chan YT, Ngui SL, Carne S, Mbisa JL; STOP-HCV Consortium. Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing. Clin Microbiol Infect 2021:S1198-743X(21)00373-6. [PMID: 34245902 DOI: 10.1016/j.cmi.2021.06.042] [Reference Citation Analysis]
90 Yato K, Matsuda M, Watanabe N, Watashi K, Aizaki H, Kato T, Tamura K, Wakita T, Muramatsu M, Suzuki R. Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105266] [Reference Citation Analysis]
91 Granozzi B, Guardigni V, Badia L, Rosselli Del Turco E, Zuppiroli A, Tazza B, Malosso P, Pieralli S, Viale P, Verucchi G. Out-of-Hospital Treatment of Hepatitis C Increases Retention in Care among People Who Inject Drugs and Homeless Persons: An Observational Study. J Clin Med 2021;10:4955. [PMID: 34768474 DOI: 10.3390/jcm10214955] [Reference Citation Analysis]
92 Kang SH, Kim MY. Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care. Clin Mol Hepatol 2021;27:100-2. [PMID: 33317234 DOI: 10.3350/cmh.2020.0312] [Reference Citation Analysis]
93 Ohlendorf V, Schäfer A, Christensen S, Heyne R, Naumann U, Link R, Herold C, Schiffelholz W, Günther R, Cornberg M, Serfert Y, Maasoumy B, Wedemeyer H, Kraus MR. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021;28:1206-18. [PMID: 34003549 DOI: 10.1111/jvh.13546] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Huiban L, Stanciu C, Muzica CM, Cuciureanu T, Chiriac S, Zenovia S, Burduloi VM, Petrea O, Sîngeap AM, Gîrleanu I, Sfarti C, Cojocariu C, Trifan A. Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania-A Population-Based Screening-The First Step to Viral Micro-Elimination. Healthcare (Basel) 2021;9:651. [PMID: 34072635 DOI: 10.3390/healthcare9060651] [Reference Citation Analysis]
95 Ortonne V, Wlassow M, Hézode C, François M, Rosa I, Pawlotsky JM, Chevaliez S. Diagnosis and monitoring of hepatitis C virus infection using the cobas® HCV test for use on the cobas® 4800 system. J Clin Virol 2021;141:104873. [PMID: 34111663 DOI: 10.1016/j.jcv.2021.104873] [Reference Citation Analysis]
96 Wildner NH, Walker A, Brauneck F, Ditt V, Peine S, Huber S, Haag F, Beisel C, Timm J, Schulze zur Wiesch J. Transcriptional Pattern Analysis of Virus-Specific CD8+ T Cells in Hepatitis C Infection: Increased Expression of TOX and Eomesodermin During and After Persistent Antigen Recognition. Front Immunol 2022;13:886646. [DOI: 10.3389/fimmu.2022.886646] [Reference Citation Analysis]
97 Isfordink CJ, van Erpecum KJ, van der Valk M, Mauser-Bunschoten EP, Makris M. Viral hepatitis in haemophilia: historical perspective and current management. Br J Haematol 2021. [PMID: 33955555 DOI: 10.1111/bjh.17438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Madsen LW, Christensen PB, Fahnøe U, Pedersen MS, Bukh J, Øvrehus A. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C. Liver Int 2021. [PMID: 34154034 DOI: 10.1111/liv.14991] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Wang Y, Cheng G, Lau G. Achieving WHO target of HCV control in Hong Kong: challenges and strategies. Glob Health Med 2021;3:276-82. [PMID: 34782869 DOI: 10.35772/ghm.2021.01075] [Reference Citation Analysis]
100 Mikulska M, Knelange N, Nicolini LA, Tridello G, Santarone S, Di Bartolomeo P, de la Camara R, Cuéllar C, Velardi A, Perruccio K, Ljungman P, Zaucha J, Piekarska A, Basak G, Karakulska-Prystupiuk E, Angelucci E, Ciceri F, Lupo-Stanghellini MT, Fouillard L, García-Cadenas I, Menconi M, Blau IW, Nassi L, Cesaro S, Styczynski J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT. J Infect 2021:S0163-4453(21)00539-9. [PMID: 34757138 DOI: 10.1016/j.jinf.2021.10.024] [Reference Citation Analysis]
101 Byrne CJ, Beer L, Inglis SK, Robinson E, Radley A, Goldberg DJ, Hickman M, Hutchinson S, Dillon JF. Real-world outcomes of rapid regional hepatitis c virus treatment scale-up among people who inject drugs in Tayside, Scotland. Aliment Pharmacol Ther 2021. [PMID: 34877667 DOI: 10.1111/apt.16728] [Reference Citation Analysis]
102 Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [PMID: 34790011 DOI: 10.3748/wjg.v27.i40.6861] [Reference Citation Analysis]
103 Rubino C, Trapani S, Indolfi G. Sofosbuvir/velpatasvir for the treatment of Hepatitis C in pediatric patients. Expert Rev Gastroenterol Hepatol 2021. [PMID: 34338120 DOI: 10.1080/17474124.2021.1963231] [Reference Citation Analysis]
104 Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-81. [PMID: 33428488 DOI: 10.1080/14787210.2021.1874351] [Reference Citation Analysis]
105 Rahimi P, Sharafi H, Bahramali G, SajadianFard F, Asadi NS, Alavian SM, Iranpur Mobarakeh V, Moravej SZ. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. Front Microbiol 2020;11:617375. [PMID: 33584581 DOI: 10.3389/fmicb.2020.617375] [Reference Citation Analysis]
106 Morales-Arraez D, Hernández-Bustabad A, Medina-Alonso MJ, Santiago-Gutiérrez LG, García-Gil S, Diaz-Flores F, Pérez-Pérez V, Nazco J, Fernandez de Rota Martin P, Gutiérrez F, Hernández-Guerra M. Telemedicine and decentralized hepatitis C treatment as a strategy to enhance retention in care among people attending drug treatment centres. Int J Drug Policy 2021;94:103235. [PMID: 33838399 DOI: 10.1016/j.drugpo.2021.103235] [Reference Citation Analysis]
107 Dotters-Katz SK, Kuller JA, Hughes BL; Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017. Am J Obstet Gynecol 2021;225:B8-B18. [PMID: 34116035 DOI: 10.1016/j.ajog.2021.06.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Mangia A, Albanese AP, Bourliére M, Craxi A, Dieterich D, Solomon S, Vanstraelen K, Hernandez C, Turnes J. Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. Adv Ther 2021;38:1397-403. [PMID: 33590446 DOI: 10.1007/s12325-021-01636-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
109 Ružić M, Rajić N, Fabri M, Urošević I, Jojkić MD, Preveden T, Pete M, Rajić N. Implementation of Microelimination Strategy in Eradication of Chronic Hepatitis C Infection in Patients with Hemophilia in the Northern region of Serbia: Is Eradication Possible? Mediterr J Hematol Infect Dis 2021;13:e2021058. [PMID: 34527210 DOI: 10.4084/MJHID.2021.058] [Reference Citation Analysis]
110 Jaquet A, Muula G, Ekouevi DK, Wandeler G. Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. Curr Epidemiol Rep 2021;8:89-96. [PMID: 34532216 DOI: 10.1007/s40471-021-00273-6] [Reference Citation Analysis]
111 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
112 Zahid H, Aslam K, Dahl EH, Abbassi W, Adan S, Van den Bergh R, Balinska MA, Luck NH. DAA treatment failures in a low-resource setting with a high burden of hepatitis C infections: a case series. Oxf Med Case Reports 2022;2022:omac049. [PMID: 35619685 DOI: 10.1093/omcr/omac049] [Reference Citation Analysis]
113 Xia H, Zhang Y, Zaongo SD, Liang J, Gong X, Hu Y, Ma P, Wang F. Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis. Ann Transl Med 2021;9:847. [PMID: 34164481 DOI: 10.21037/atm-21-1297] [Reference Citation Analysis]
114 Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators., Spanish GEHEP-004 Collaborators., Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol 2021;74:801-10. [PMID: 33220331 DOI: 10.1016/j.jhep.2020.11.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
115 Semmler G, Binter T, Kozbial K, Schwabl P, Chromy D, Bauer D, Simbrunner B, Müllner-Bucsics T, Scheiner B, Stättermayer A, Pinter M, Steindl-Munda P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. J Pers Med 2021;11:281. [PMID: 33917196 DOI: 10.3390/jpm11040281] [Reference Citation Analysis]
116 Sintusek P, Thanapirom K, Komolmit P, Poovorawan Y. Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030. World J Gastroenterol 2022; 28(3): 290-309 [DOI: 10.3748/wjg.v28.i3.290] [Reference Citation Analysis]
117 D'Ambrosio R, Degasperi E, Lampertico P. Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. J Hepatocell Carcinoma 2021;8:713-39. [PMID: 34235108 DOI: 10.2147/JHC.S292139] [Reference Citation Analysis]
118 EASL Recommendations on Treatment of Hepatitis C Panel. Electronic address: easloffice@easloffice.eu. Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues". J Hepatol 2021;74:474-5. [PMID: 33229012 DOI: 10.1016/j.jhep.2020.10.025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
119 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
120 Rossotti R, Merli M, Mazzarelli C, De Carlis RM, Travi G, Vecchi M, Viganò R, Lauterio A, Raimondi A, Belli LS, De Carlis LG, Puoti M. Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.05.001] [Reference Citation Analysis]
121 Liu C, Liu C, Su T, Tseng T, Chen P, Kao J. Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response. Adv in Digestive Medicine. [DOI: 10.1002/aid2.13302] [Reference Citation Analysis]
122 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
123 Sasso FC, Pafundi PC, Caturano A, Galiero R, Vetrano E, Nevola R, Petta S, Fracanzani AL, Coppola C, Di Marco V, Solano A, Lombardi R, Giordano M, Craxi A, Perrella A, Sardu C, Marfella R, Salvatore T, Adinolfi LE, Rinaldi L. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2021;31:2345-53. [DOI: 10.1016/j.numecd.2021.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 McCormick CA, Domegan L, Carty PG, Drew R, McAuliffe FM, O'Donohoe O, White N, Garvey P, O'Grady M, De Gascun CF, McCormick PA. Routine screening for hepatitis C in pregnancy is cost-effective in a large urban population in Ireland: a retrospective study. BJOG 2022;129:322-7. [PMID: 34706147 DOI: 10.1111/1471-0528.16984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Ampuero J, Carmona I, Sousa F, Rosales JM, Lopez-Garrido A, Casado M, Figueruela B, Aparicio A, Andrade R, Guerra-Veloz MF, Maraver M, Pascasio JM, Estevez M, Romero-Gomez M. A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. Am J Gastroenterol 2021. [PMID: 34817975 DOI: 10.14309/ajg.0000000000001503] [Reference Citation Analysis]
126 Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C. [Chronic kidney injury in patients with liver diseases - Reappraising pathophysiology and treatment options]. Z Gastroenterol 2021;59:560-79. [PMID: 33728618 DOI: 10.1055/a-1402-1502] [Reference Citation Analysis]
127 Forns X, Feld JJ, Dylla DE, Pol S, Chayama K, Hou J, Heo J, Lampertico P, Brown A, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Gordon SC, Jacobson IM. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. Adv Ther 2021;38:3409-26. [PMID: 34021887 DOI: 10.1007/s12325-021-01753-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
128 Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Reference Citation Analysis]
129 Neag MA, Mitre AO, Catinean A, Buzoianu AD. Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. World J Gastroenterol 2021; 27(43): 7446-7461 [PMID: 34887642 DOI: 10.3748/wjg.v27.i43.7446] [Reference Citation Analysis]
130 Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Kao JH, Chuang WL, Lin HC, Yu ML. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int 2021;41:1265-77. [PMID: 33655714 DOI: 10.1111/liv.14849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
131 Lazarus JV, Villota-rivas M, Fernández I, Gea F, Ryan P, López SA, Guy D, Calleja JL, García-samaniego J. A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid. Commun Med 2022;2. [DOI: 10.1038/s43856-022-00077-9] [Reference Citation Analysis]
132 Muzica CM, Stanciu C, Cijevschi-prelipcean C, Girleanu I, Huiban L, Petrea OC, Singeap A, Cojocariu C, Cuciureanu T, Sfarti C, Zenovia S, Chriac S, Stefanescu G, Ciortescu I, Lupașcu-ursulescu C, Miftode E, Trifan A. Long-term Risk of Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy in Compensated Liver Cirrhosis Induced by Hepatitis C Virus Infection. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.115910] [Reference Citation Analysis]
133 Eldafashi N, Darlay R, Shukla R, McCain MV, Watson R, Liu YL, McStraw N, Fathy M, Fawzy MA, Zaki MYW, Daly AK, Maurício JP, Burt AD, Haugk B, Cordell HJ, Bianco C, Dufour JF, Valenti L, Anstee QM, Reeves HL. A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? Cancers (Basel) 2021;13:1412. [PMID: 33808740 DOI: 10.3390/cancers13061412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
134 Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, Toyoda H, Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS One 2021;16:e0257166. [PMID: 34506563 DOI: 10.1371/journal.pone.0257166] [Reference Citation Analysis]
135 Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
136 Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J. The Practicability of the Xpert HCV Viral Load Fingerstick Point-of-Care Assay in Primary Care Settings. Viruses 2021;13:2327. [PMID: 34835133 DOI: 10.3390/v13112327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Kermani FR, Hosseini KM, Kafi-abad SA, Maghsudlu M, Sharifi Z, Mansournia MA. Quantification of hepatitis C virus in viremic blood donors in Iran: Need to reinforce post-donation follow up. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103353] [Reference Citation Analysis]
138 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Reference Citation Analysis]
139 Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
140 Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment Pharmacol Ther 2021. [PMID: 34812502 DOI: 10.1111/apt.16691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Schwarz T, Horváth I, Fenz L, Schmutterer I, Rosian-schikuta I, Mårdh O. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. International Journal of Drug Policy 2022;102:103588. [DOI: 10.1016/j.drugpo.2022.103588] [Reference Citation Analysis]
142 Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073 [DOI: 10.4254/wjh.v14.i6.1053] [Reference Citation Analysis]
143 D'Ambrosio R, Ioannou GN. Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication. Hepatol Commun 2021;5:1465-8. [PMID: 34510832 DOI: 10.1002/hep4.1733] [Reference Citation Analysis]
144 Flores GL, Mota JC, da Silva Andrade LT, Lopes RS, Bastos FI, Villar LM, Komatsu H. Performance of HCV Antigen Testing for the Diagnosis and Monitoring of Antiviral Treatment: A Systematic Review and Meta-Analysis. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/7348755] [Reference Citation Analysis]
145 Cornberg M, Manns MP. The curing regimens of HCV: A SWOT analysis. Antivir Ther 2022;27:13596535211072672. [PMID: 35491553 DOI: 10.1177/13596535211072672] [Reference Citation Analysis]
146 García-Crespo C, Gallego I, Soria ME, de Ávila AI, Martínez-González B, Vázquez-Sirvent L, Lobo-Vega R, Moreno E, Gómez J, Briones C, Gregori J, Quer J, Domingo E, Perales C. Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus. Viruses 2021;13:616. [PMID: 33916702 DOI: 10.3390/v13040616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Bobardt M, Ramirez CM, Baum MM, Ure D, Foster R, Gallay PA. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. PLoS One 2021;16:e0251934. [PMID: 34014993 DOI: 10.1371/journal.pone.0251934] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Morgan JR, Savinkina A, Pires Dos Santos AG, Xue Z, Shilton S, Linas B. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Adv Ther 2021;38:1690-700. [PMID: 33590445 DOI: 10.1007/s12325-021-01647-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Gane E, de Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, Calleja JL, Xue Z, Burroughs M, Gutierrez JA. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Viral Hepat 2021;28:1635-42. [PMID: 34448313 DOI: 10.1111/jvh.13600] [Reference Citation Analysis]
150 Morelli MC, Rendina M, La Manna G, Alessandria C, Pasulo L, Lenci I, Bhoori S, Messa P, Biancone L, Gesualdo L, Russo FP, Petta S, Burra P; Italian Association for the Study of Liver, and the Italian Society of Nephrology. Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). Dig Liver Dis 2021;53 Suppl 2:S49-86. [PMID: 34074490 DOI: 10.1016/j.dld.2021.03.035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Tseng C, Liu W, Chen C, Chang T, Tseng K. Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07326-1] [Reference Citation Analysis]
152 Marascio N, Rotundo S, Quirino A, Matera G, Liberto MC, Costa C, Russo A, Trecarichi EM, Torti C. Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice . World J Gastroenterol 2022; 28(12): 1226-1238 [DOI: 10.3748/wjg.v28.i12.1226] [Reference Citation Analysis]
153 Harney BL, Whitton B, Paige E, Brereton R, Weiss R, Membrey D, Wade AJ, Iser D, Kemp W, Roberts SK, Spelman T, Sacks-Davis R, Hellard ME, Doyle JS. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia. Liver Int 2021. [PMID: 34821021 DOI: 10.1111/liv.15107] [Reference Citation Analysis]
154 Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Reference Citation Analysis]
155 Winter RJ, Holmes JA, Papaluca TJ, Thompson AJ. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. Viruses 2022;14:497. [DOI: 10.3390/v14030497] [Reference Citation Analysis]
156 Badami E, Busà R, Douradinha B, Russelli G, Miceli V, Gallo A, Zito G, Conaldi PG, Iannolo G. Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches. World J Gastroenterol 2022; 28(22): 2417-2428 [DOI: 10.3748/wjg.v28.i22.2417] [Reference Citation Analysis]
157 Ryan P, Valencia J, Cuevas G, Torres-Macho J, Troya J, Pueyo Á, José Muñoz-Gómez M, Muñoz-Rivas N, Vázquez-Morón S, Martinez I, Lazarus JV, Resino S. Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. Int J Drug Policy 2021;96:103424. [PMID: 34429222 DOI: 10.1016/j.drugpo.2021.103424] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Novel combined single dose anti-hepatitis C therapy: a pilot study. Sci Rep 2021;11:4623. [PMID: 33633233 DOI: 10.1038/s41598-021-84066-3] [Reference Citation Analysis]
159 Cohen-Bucay A, Francis JM, Gordon CE. Progress in hepatitis C virus management in chronic kidney disease. Curr Opin Nephrol Hypertens 2021;30:493-500. [PMID: 34054074 DOI: 10.1097/MNH.0000000000000729] [Reference Citation Analysis]
160 Howe AY, Rodrigo C, Cunningham E, Douglas MW, Dietz J, Grebely J, Popping S, Sfalcin JA, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, di Maio VC, Chulanov V, Pawlotsky J, Harrigan PR, Ceccherini-silberstein F, Garcia F, Martinello M, Matthews G, Fernando FF, Esteban JI, Müllhaupt B, Wiesch JSZ, Buggisch P, Neumann-haefelin C, Berg T, Berg CP, Schattenberg JM, Moreno C, Stauber R, Lloyd A, Dore G, Applegate T, Ignacio J, Garcia-cehic D, Gregori J, Rodriguez-frias F, Rando A, Angelico M, Andreoni M, Babudieri S, Bertoli A, Cento V, Coppola N, Craxì A, Paolucci S, Parruti G, Pasquazzi C, Perno CF, Teti E, Vironet C, Lannergård A, Duberg A, Aleman S, Gutteberg T, Soulier A, Gourgeon A, Chevaliez S, Pol S, Carrat F, Salmon D, Kaiser R, Knopes E, Gomes P, de Kneght R, Rijnders B, Poljak M, Lunar M, Usubillaga R, Seguin C, Tay E, Wilson C, Wang DS, George J, Kok J, Pérez AB, Chueca N, García-deltoro M, Martínez-sapiña AM, Lara-pérez MM, García-bujalance S, Aldámiz-echevarría T, Vera-méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-arboledas JC, Poyato A, Téllez F, Rivero-juárez A, Merino D, Vivancos-gallego MJ, Rosales-zábal JM, Ocete MD, Simón MÁ, Rincón P, Reus S, De la Iglesia A, García-arata I, Jiménez M, Jiménez F, Hernández-quero J, Galera C, Balghata MO, Primo J, Masiá M, Espinosa N, Delgado M, von-Wichmann MÁ, Collado A, Santos J, Mínguez C, Díaz-flores F, Fernández E, Bernal E, De Juan J, Antón JJ, Vélez M, Aguilera A, Navarro D, Arenas JI, Fernández C, Espinosa MD, Ríos MJ, Alonso R, Hidalgo C, Hernández R, Téllez MJ, Rodríguez FJ, Antequera P, Delgado C, Martín P, Crespo J, Becerril B, Pérez O, García-herola A, Montero J, Freyre C, Grau C, Cabezas J, Jimenez M, Rodriguez MAM, Quilez C, Pardo MR, Muñoz-medina L, Figueruela B. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100462] [Reference Citation Analysis]
161 Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Biliotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ieluzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA; PITER Collaborating Group. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Dig Liver Dis 2021:S1590-8658(21)00137-7. [PMID: 33893040 DOI: 10.1016/j.dld.2021.03.020] [Reference Citation Analysis]
162 El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
163 Mancebo Martínez A, Núñez Serrano P, Fernández de Cañete Camacho JC, Moreno Planas JM. Hepatitis C Virus Core Antigen as an Alternative to RNA in the Assessment of Response to Treatment with Direct-acting Oral Antivirals. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.118579] [Reference Citation Analysis]
164 Lin JJ, Loucks CM, Trueman JN, Drögemöller BI, Wright GEB, Yoshida EM, Ford JA, Lee SS, Kim RB, Al-Judaibi B, Schwarz UI, Ramji A, Tam E, Ross CJ, Carleton BC. Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. Biomed Pharmacother 2021;143:112195. [PMID: 34562771 DOI: 10.1016/j.biopha.2021.112195] [Reference Citation Analysis]
165 De A, Roy A, Verma N, Mishra S, Premkumar M, Taneja S, Singh V, Duseja A. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis. Nephrology (Carlton) 2021. [PMID: 34453374 DOI: 10.1111/nep.13968] [Reference Citation Analysis]
166 Hagymási K. The Nobel Prize in Physiology or Medicine-2020. Struct Chem 2021;:1-5. [PMID: 33584076 DOI: 10.1007/s11224-021-01731-z] [Reference Citation Analysis]
167 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Reference Citation Analysis]
168 Cacoub P, Comarmond C, Vieira M, Régnier P, Saadoun D. HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma. J Hepatol 2021:S0168-8278(21)02084-5. [PMID: 34600000 DOI: 10.1016/j.jhep.2021.09.023] [Reference Citation Analysis]
169 Yamana Y, Kanda T, Matsumoto N, Honda M, Kumagawa M, Sasaki R, Kanezawa S, Mizutani T, Yamagami H, Masuzaki R, Ishii T, Nirei K, Moriyama M. Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan. J Clin Med 2021;10:5529. [PMID: 34884231 DOI: 10.3390/jcm10235529] [Reference Citation Analysis]
170 Kuo YH, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus. Kaohsiung J Med Sci 2021. [PMID: 34687140 DOI: 10.1002/kjm2.12465] [Reference Citation Analysis]
171 Dai CY, Chuang WL, Yu ML. EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues. J Hepatol 2021;74:473-4. [PMID: 33223214 DOI: 10.1016/j.jhep.2020.10.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Chang KC, Tung SY, Wei KL, Shen CH, Hsieh YY, Chen WM, Chen YH, Chen CH, Yen CW, Xu HW, Tung WL, Hung CH, Lu SN, Chang TS. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. Sci Rep 2021;11:13543. [PMID: 34188161 DOI: 10.1038/s41598-021-93095-x] [Reference Citation Analysis]
173 Parczewski M, Janczewska E, Pisula A, Dybowska D, Łojewski W, Witor A, Wawrzynowicz-Syczewska M, Socha Ł, Krygier R, Knysz B, Musialik J, Urbańska A, Scheibe K, Jaroszewicz J. HCV resistance-associated substitutions following direct-acting antiviral therapy failure - Real-life data from Poland. Infect Genet Evol 2021;93:104949. [PMID: 34087494 DOI: 10.1016/j.meegid.2021.104949] [Reference Citation Analysis]
174 Yen H, Chen Y, Lai J, Chen H, Yao C, Huang S, Liu I, Zeng Y, Yang F, Siao F, Chen M, Su P. Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis. JCM 2022;11:1853. [DOI: 10.3390/jcm11071853] [Reference Citation Analysis]
175 Chen Y, Chang T, Chen C, Cheng P, Lo C, Mo L, Chen C, Huang C, Kuo H, Huang Y, Tai C, Peng C, Bair M, Yeh M, Lin C, Lin C, Lee P, Chong L, Hung C, Huang J, Yang C, Hu J, Lin C, Wang C, Su W, Hsieh T, Lin C, Tsai W, Lee T, Chen G, Wang S, Chang C, Yang S, Wu W, Huang C, Hsiung C, Kao C, Tsai P, Liu C, Lee M, Dai C, Kao J, Chuang W, Lin H, Chen C, Tseng K, Yu M; on behalf of TACR investigators. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. Viruses 2022;14:333. [DOI: 10.3390/v14020333] [Reference Citation Analysis]
176 Besombes J, Pronier C, Lefevre C, Lagathu G, Maillard A, Grolhier C, Thibault V. Performances of NeuMoDx™, a random-access system for hepatitis B virus DNA and hepatitis C virus RNA quantification. Clin Microbiol Infect 2021;27:1693.e9-1693.e15. [PMID: 33677082 DOI: 10.1016/j.cmi.2021.02.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Alqahtani SA, Colombo MG. Treating paediatric hepatitis C in the era of direct-acting antiviral agents. Liver Int 2021;41:1189-200. [PMID: 33533543 DOI: 10.1111/liv.14810] [Reference Citation Analysis]
178 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
179 Yilmaz B, Ruckstuhl L, Müllhaupt B, Magenta L, Kuster MH, Clerc O, Torgler R, Semmo N. Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. Pharmaceuticals (Basel) 2021;14:931. [PMID: 34577631 DOI: 10.3390/ph14090931] [Reference Citation Analysis]
180 Zeng DY, Li JM, Lin S, Dong X, You J, Xing QQ, Ren YD, Chen WM, Cai YY, Fang K, Hong MZ, Zhu Y, Pan JS. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019. J Hepatol 2021;75:547-56. [PMID: 33961940 DOI: 10.1016/j.jhep.2021.04.035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Kim KA, Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Ki M, Choi HY, Paik D, Jeong SH. Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID. Epidemiol Health 2021;43:e2021077. [PMID: 34645207 DOI: 10.4178/epih.e2021077] [Reference Citation Analysis]
182 Sanduzzi-Zamparelli M, Mariño Z, Lens S, Sapena V, Iserte G, Pla A, Granel N, Bartres C, Llarch N, Vilana R, Nuñez I, Darnell A, Belmonte E, García-Criado A, Díaz A, Muñoz-Martinez S, Ayuso C, Bianchi L, Fuster-Anglada C, Rimola J, Forner A, Torres F, Bruix J, Forns X, Reig M. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. J Hepatol 2021:S0168-8278(21)02228-5. [PMID: 34856322 DOI: 10.1016/j.jhep.2021.11.023] [Reference Citation Analysis]
183 Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma 2021;8:837-50. [PMID: 34350139 DOI: 10.2147/JHC.S308587] [Reference Citation Analysis]
184 Mastrorosa I, Tempestilli M, Notari S, Lorenzini P, Fabbri G, Grilli E, Bellagamba R, Vergori A, Cicalini S, Ammassari A, Agrati C, Antinori A. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. Eur J Drug Metab Pharmacokinet 2021. [PMID: 34623616 DOI: 10.1007/s13318-021-00725-w] [Reference Citation Analysis]
185 Djebali-Trabelsi A, Marot A, André C, Deltenre P. Large-scale screening is not useful for identifying individuals with hepatitis B or C virus infection: A prospective Swiss study. J Viral Hepat 2021. [PMID: 34342098 DOI: 10.1111/jvh.13588] [Reference Citation Analysis]